 This outside clinical trial experience is contrary to findings from BOLERO-2, where the number of patients still taking full-dose 10mg of everolimus at 4, 8, and 12 weeks is 77.8, 75.6, and 75.6, respectively. These findings are in concordance with non-interventional studies. However, findings might be biased by positive pre-selection. 